Cambridge, UK, 18 September 2017 – Microbiotica, a leading player in microbiome-based therapeutics, today announces that CEO, Dr Mike Romanos, will present at the Annual Microbiome Summit: Translating into Diagnostics and BioTherapeutics, 21-22 September, in Vienna, Austria.
Dr Romanos’ talk “The Discovery of Novel Bacterial Therapeutics and Biomarkers Based on Deep Microbiome Analysis” will take place on 22nd September at 2.30 pm. His talk will focus on the importance of identifying gut bacteria with patient phenotype, the role of gut bacteria in immunotherapy response, and how these factors are key to the discovery of bacterial therapeutics.
The Summit brings together companies at the cutting-edge of microbiome research and provides a platform to engage and discuss current challenges, best practice and the future of microbiome in precision medicine.
Microbiotica, spun-out of the Wellcome Trust Sanger Institute in 2016, was formed around ground-breaking research led by Dr Trevor Lawley and is focused on microbiome biology, and its use in medicine, covering both novel bacterial therapeutics and patient diagnostics.